Dabbagh, Ali http://orcid.org/0000-0003-4344-8131
Rajaei, Samira
Ghahremani, Mehdi
Fathi, Mohammad
Massoudi, Nilofar
Tavana, Sasan
Fani, Kamal
Nooraee, Navid
Malekpour Alamdari, Nasser
Besharat, Sara
Najafi Abrandabadi, Arash
Pirsalehi, Ali
Khabiri Khatiri, Mohammad Ali
Funding for this research was provided by:
Shahid Beheshti University of Medical Sciences (22959)
Tekzima Drug Alborz Company, Iran (provided the drugs as a support to the study)
Article History
Received: 14 October 2020
Accepted: 16 October 2020
First Online: 11 November 2020
Ethics approval and consent to participate
: Name of ethics committee: Shahid Beheshti University of Medical Sciences, Tehran, Iran.Ethics committee reference number: IR.SBMU.RETECH.REC.1399.016; Approval date: 2020-03-28, 1399/01/09I certify that this trial has received ethical approval from the aforementioned ethical committee. In addition, we intend to obtain consent from participants to participate in the study (or from their parent or legal guardian in the case of children under 16).
: Not applicable.
: The surfactant vials were provided by Tekzima Drug Alborz Company, Tehran, Iran which provided the drugs as a support to the study. The drug was provided as “Beraksurf” as 100 mg in 4 mL vials. Except for the supply of the drugs, there is no relationship between the researchers and the latter company or any other company.